Related Experiment Video
Updated: Jun 22, 2026

Quantification of Intracellular Growth Inside Macrophages is a Fast and Reliable Method for Assessing the Virulence of Leishmania Parasites
Published on: March 16, 2018
Development and Characterization of an Avirulent Leishmania major Strain
Mukesh Kumar Jha1, Aditya Y Sarode1, Neelam Bodhale2
1National Centre for Cell Science, Savitribai Phule Pune University, Pune, Maharashtra 411007, India.
Abstract:
Leishmania major causes cutaneous leishmaniasis. An antileishmanial vaccine for humans is unavailable. In this study, we report development of two attenuated L. major strains-5ASKH-HP and LV39-HP-by continuous culture (high passage) of the corresponding virulent strains (low passage). Both avirulent strains showed similar changes in proteome profiles when analyzed by surface-enhanced laser desorption ionization mass spectrometry. Liquid chromatography-mass spectrometry and microarray characterization of 5ASKH strains revealed substantially altered gene and protein expression profiles, respectively. Both virulent and avirulent L. major strains grew comparably in culture, but the avirulent strain survived significantly less in BALB/c-derived peritoneal macrophages. Both attenuated strains failed to infect BALB/c mice and elicited IFN-γ, but not IL-4 and IL-10, responses. 5ASKH-HP parasites failed to induce significant infection even in severely immunocompromised- SCID or inducible NO synthase-, CD40-, or IL-12-deficient mice, indicating attenuation. The avirulent strain induced less IL-10, but higher IL-12, in macrophages. The avirulent strain failed to reduce CD40 relocation to the detergent-resistant membrane domain and to inhibit CD40-induced phosphorylation of the kinases Lyn and protein kinase C-β and MAPKs MKK-3/6 and p38MAPK or to upregulate MEK-1/2 and ERK-1/2 in BALB/c-derived peritoneal macrophages. The virulent and the avirulent strains reciprocally modulated CD40-induced Ras-mediated signaling through PI-3K and Raf-1. Avirulent 5ASKH-primed BALB/c mice were protected against virulent L. major challenge infection. The loss of virulence accompanied by substantially altered proteome profiles and the elicitation of host-protective immune responses indicate plausibly irreversible attenuation of the L. major strain and its potential use as a vaccine strain.
Insights
Researchers developed attenuated Leishmania major strains for a potential vaccine against cutaneous leishmaniasis. These avirulent strains showed altered protein profiles and induced protective immunity in mice.
Area of Science:
- Parasitology
- Immunology
- Vaccine Development
Background:
- Cutaneous leishmaniasis, caused by Leishmania major, lacks an effective human vaccine.
- Development of attenuated strains is a strategy for live vaccines against parasitic infections.
Purpose of the Study:
- To develop and characterize attenuated Leishmania major strains for vaccine potential.
- To assess the immunogenicity and protective efficacy of these attenuated strains.
Main Methods:
- Attenuated Leishmania major strains (5ASKH-HP, LV39-HP) were generated by high-passaging virulent strains.
- Proteomic, transcriptomic, and proteomic analyses were performed.
- In vitro macrophage survival assays and in vivo mouse infection models (BALB/c, SCID, deficient mice) were used.
- Immune responses (cytokine production, signaling pathways) and protection against virulent challenge were evaluated.
Main Results:
- Attenuated strains exhibited altered proteome and gene expression profiles compared to virulent strains.
- Avirulent strains survived poorly in macrophages and failed to infect immunocompetent or immunocompromised mice.
- Attenuated strains elicited protective Th1-biased immune responses (IFN-γ) and protected mice against virulent L. major challenge.
Conclusions:
- The developed attenuated Leishmania major strains demonstrate plausible irreversible attenuation.
- These strains show potential as a live vaccine candidate for cutaneous leishmaniasis due to induced host-protective immunity.
Related Concept Videos
Leishmaniasis
Antiprotozoal Agents

